# OnCo record pd-l1-cps (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/pd-l1-cps/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "pd-l1-cps" ;
  schema:name "PD-L1 CPS (combined positive score)"@en ;
  schema:alternateName "PD-L1 CPS"@en, "CPS"@en, "combined positive score"@en, "PD-L1 combined positive score"@en, "CPS >= 1"@en, "CPS >= 10"@en, "PD-L1 CPS 1"@en, "PD-L1 CPS 10"@en, "CPS≥1"@en, "CPS≥10"@en ;
  schema:description "CPS counts every PD-L1-stained cell in the tumour, immune cells included, and divides by the number of tumour cells. Pembrolizumab labels use CPS 1 or CPS 10 as the gate in head and neck, stomach, oesophageal, cervical, ovarian and triple-negative breast cancer."@en ;
  schema:url <https://onco.cc/biomarkers/pd-l1-cps/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:tag "biomarker", "pd-l1" ;
  onco:related <https://onco.cc/biomarkers/pd-l1-tps/>, <https://onco.cc/biomarkers/pd-l1-ic-score/>, <https://onco.cc/biomarkers/pd-l1-tc-score/> ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-her2-positive/>, <https://onco.cc/cancers/gastric-pdl1-high/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/> ;
  onco:terms <https://onco.cc/terms/cps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/ihc/> .